Top Story Today
The Biopharma Pipeline Shrank for the First Time Since the Mid-1990s
The global drug development pipeline dropped to 22,940 programs at the start of 2026, a net loss of 935 from the prior year. That breaks a growth streak stretching back three decades. The culprits: a brutal funding drought for early-stage biotechs, Big Pharma trimming weaker candidates instead of throwing spaghetti at the wall, and a patent cliff that will wipe out $176 billion in annual revenue by 2029. Oncology still dominates new entrants (38.6%), but neurological diseases are quietly surging, a meaningful comeback for a space once considered a graveyard.
Why it matters: This isn't just a bad year for R&D; it may signal a structural shift toward fewer bets, bigger bets, and more acquisition-driven pipelines. The era of relentless expansion is over, and the ripple effects will shape biotech investment, drug pricing, and patient access for years.
Read more →Policy & Politics
The White House Wants to Cut $15.8 Billion From HHS (Including a $5B Hit to NIH)
The FY2027 budget proposal would slash NIH funding by roughly 10%, threatening the basic science grants that seed nearly every major drug discovery. Congress has killed proposals like this before (last year's even deeper cuts were rejected), but the uncertainty is already doing real damage: 2,300 grants worth $2.5 billion were terminated in FY2025, and university labs have frozen hiring.
Read more →100% Pharma Tariffs Sound Scary. Most Imports Won't Actually Pay Them.
The Trump administration announced 100% tariffs on imported brand-name drugs, but the fine print tells a different story. Companies can sign confidential deals earning them a 0% rate through onshoring and MFN pricing agreements. Generics (91% of U.S. prescriptions) are completely exempt. Small biotechs without U.S. manufacturing, though, are the ones left sweating.
Read more →Clinical Setbacks & Wins
Gilead Kills Its Weekly HIV Pill After the Drug Turned on Patients' Immune Cells
Gilead terminated its WONDERS-2 trial after the once-weekly oral HIV combo started attacking the very CD4+ T-cells it was supposed to protect. The $20.8 billion HIV franchise isn't in danger, but the setback raises hard questions about whether long-acting oral antiretrovirals are pharmacologically feasible. Gilead's backup plan: a Merck-partnered weekly pill now heading to Phase 3.
Read more →Tecartus Earns Full FDA Approval for Mantle Cell Lymphoma
Kite Pharma's Tecartus converted from accelerated to traditional FDA approval for relapsed mantle cell lymphoma, posting a 91% response rate. It's a proof of concept that the confirmatory pathway actually works for cell therapies.
Read more →Funding & Deals
A Three-Year-Old Beijing Startup Just Raised $250M in Four Months
Syneron Bio closed a $150 million Series B, bringing its total haul since late 2025 to $250 million. The draw: an AI platform that designs macrocyclic peptides, a "Goldilocks" drug class sitting between small molecules and biologics. AstraZeneca doubled down after signing a deal worth up to $3.4 billion in milestones, and sovereign wealth funds from Abu Dhabi and Singapore joined the round.
Read more →